 |
|
|
|
|
|
|
|
|
|
|
 |
|
|||||||||
 |
 |
 |
 |
 |
 |
 |
 |
|
||
 |
 |
 |
|
|||||||
 |
|
|||||||||
 |
|
|||||||||
Alert Number 145
Date: January 18, 2024
There is an ongoing debate about FCR versus PCR combo therapies. Which is better? Which has higher efficacy, and lower toxicity? Does it really make a difference which of the two purine analogs, fludarabine or pentostatin, is used? Comparing the results of these two trials is not easy but we nevertheless make a brave attempt in our latest article, Comparing Apples and Kumquats in which we give you an update on these and other important clinical trials.
You might remember we had serious concerns about the design of the FCR + Mitoxantrone clinical trial offered at M. D. Anderson. We brought it to the attention of the researchers (and the manufacturer of mitoxantrone) that they need to include FDA mandated screening of patients for cardiac risk prior to recruiting them for this trial. We are delighted to report the newly updated protocol for the FCR + M trial includes cardiac screening as one of the criteria used for recruiting patients. I would like to take this opportunity to thank the many patients who corresponded with us about this trial, as well as our unofficial but definitely blue ribbon advisory panel, whose feedback made it easier for us to tilt with this particularly powerful windmill. You can read about the continuing saga of FCR + M as well in this latest article.
Be well,
Chaya
_____
NOTICE: This page from the Topics Alert archive was originally emailed to subscribers of Topics Alert, a free service of CLL Topics Inc. If you are not a subscriber and you wish to receive email Alerts, please register at the Topics Alert subscription page. The content of this page is intended for information only and it is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.
———
Disclaimer: The content of this website is intended for information only and is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.
Copyright Notice:
Copyright © 2024-2007 CLL Topics, Inc. All Rights Reserved.
All materials contained on this site are protected by United States copyright law and may not be reproduced, distributed, transmitted, displayed, published or broadcast without the prior written permission of CLL Topics, Inc. You may not alter or remove any trademark, copyright or other notice from copies of the content.
However, you may download and print material from CLLTopics.org exclusively for your personal, noncommercial use.
———
